Dr Reddys Laboratories Ltd
About Dr Reddys Laboratories Ltd
Categories
-
Country/Region:India
-
On CPHI since:2019
CPHI Milan 2026
Fiera Milano, Italy
CPHI India 2026
IICC, Yashobhoomi, Dwarka, Delhi
Products from Dr Reddys Laboratories Ltd (5)
-
Product Abiraterone Acetate
We supply Abiraterone Acetate in bulk quantities. Learn more on api.drreddys.com. -
Product Atorvastatin
We supply Atorvastatin as a generic API in commercial quantities. -
Product Apremilast
As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast -
Product Apremilast
As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast -
Product Apremilast
As one of the largest API supplier worldwide, we are your reliable partner for the supply of high quality commercial quantities of Apremilast
Dr Reddys Laboratories Ltd Resources (5)
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic and Wegovy, addressing the growing demand for accessible treatments in India.
-
News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 1
This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force?
-
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries.
-
News Aurigene Pharmaceutical Services to expand biologics CDMO capacity with a new biomanufacturing facility
Aurigene Pharma announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by offering end-to-end and high-quality services for antibodies, proteins, and viral vectors. -
News CPHI Podcast Series: The importance of Pharma 4.0 to innovation leads in India
In this latest episode from the CPHI Podcast Series, Digital Editor Lucy Chard speaks to Sanjay Sharma, Global Head of Manufacturing, from Dr Reddy’s. Sanjay has over 26 years of experience in roles encompassing sales, the supply chain, and technical operations.

